716 related articles for article (PubMed ID: 36581880)
21. The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure.
Ji PJ; Zhang ZY; Yan Q; Cao HL; Zhao YJ; Yang B; Li J
ESC Heart Fail; 2023 Apr; 10(2):1314-1325. PubMed ID: 36722326
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.
Anker SD; Butler J; Filippatos GS; Jamal W; Salsali A; Schnee J; Kimura K; Zeller C; George J; Brueckmann M; Zannad F; Packer M;
Eur J Heart Fail; 2019 Oct; 21(10):1279-1287. PubMed ID: 31523904
[TBL] [Abstract][Full Text] [Related]
23. SGLT2 inhibitors among patients with heart failure with preserved ejection fraction: A meta-analysis of randomised controlled trials.
Jaiswal A; Jaiswal V; Ang SP; Hanif M; Vadhera A; Agrawal V; Kumar T; Nair AM; Borra V; Garimella V; Ishak A; Wajid Z; Song D; Attia AM; Huang H; Aguilera Alvarez VH; Shrestha AB; Biswas M
Medicine (Baltimore); 2023 Sep; 102(39):e34693. PubMed ID: 37773799
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction.
Cohen LP; Isaza N; Hernandez I; Lewis GD; Ho JE; Fonarow GC; Kazi DS; Bellows BK
JAMA Cardiol; 2023 May; 8(5):419-428. PubMed ID: 36870047
[TBL] [Abstract][Full Text] [Related]
25. Clinical characteristics, one-year change in ejection fraction and long-term outcomes in patients with heart failure with mid-range ejection fraction: a multicentre prospective observational study in Catalonia (Spain).
Farré N; Lupon J; Roig E; Gonzalez-Costello J; Vila J; Perez S; de Antonio M; Solé-González E; Sánchez-Enrique C; Moliner P; Ruiz S; Enjuanes C; Mirabet S; Bayés-Genís A; Comin-Colet J;
BMJ Open; 2017 Dec; 7(12):e018719. PubMed ID: 29273666
[TBL] [Abstract][Full Text] [Related]
26. Effect of digoxin in patients with heart failure and mid-range (borderline) left ventricular ejection fraction.
Abdul-Rahim AH; Shen L; Rush CJ; Jhund PS; Lees KR; McMurray JJV;
Eur J Heart Fail; 2018 Jul; 20(7):1139-1145. PubMed ID: 29493058
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis.
Butler J; Usman MS; Khan MS; Greene SJ; Friede T; Vaduganathan M; Filippatos G; Coats AJS; Anker SD
ESC Heart Fail; 2020 Dec; 7(6):3298-3309. PubMed ID: 33586910
[TBL] [Abstract][Full Text] [Related]
28. SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction.
Jhund PS
Heart Fail Clin; 2022 Oct; 18(4):579-586. PubMed ID: 36216487
[TBL] [Abstract][Full Text] [Related]
29. Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF: The DELIVER Trial.
Peikert A; Bart BA; Vaduganathan M; Claggett BL; Kulac IJ; Kosiborod MN; Desai AS; Jhund PS; Lam CSP; Inzucchi SE; Martinez FA; de Boer RA; Hernandez AF; Shah SJ; Petersson M; Langkilde AM; McMurray JJV; Solomon SD; Vardeny O
JACC Heart Fail; 2024 Apr; 12(4):631-644. PubMed ID: 37767674
[TBL] [Abstract][Full Text] [Related]
30. Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction - Results from the EMPULSE trial.
Tromp J; Kosiborod MN; Angermann CE; Collins SP; Teerlink JR; Ponikowski P; Biegus J; Ferreira JP; Nassif ME; Psotka MA; Brueckmann M; Blatchford JP; Steubl D; Voors AA
Eur J Heart Fail; 2024 Apr; 26(4):963-970. PubMed ID: 38572654
[TBL] [Abstract][Full Text] [Related]
31. Impact of left ventricular ejection fraction phenotypes on healthcare resource utilization in hospitalized heart failure: a secondary analysis of REPORT-HF.
Farmakis D; Tromp J; Marinaki S; Ouwerkerk W; Angermann CE; Bistola V; Dahlstrom U; Dickstein K; Ertl G; Ghadanfar M; Hassanein M; Obergfell A; Perrone SV; Polyzogopoulou E; Schweizer A; Boletis I; Cleland JGF; Collins SP; Lam CSP; Filippatos G
Eur J Heart Fail; 2023 Jun; 25(6):818-828. PubMed ID: 36974770
[TBL] [Abstract][Full Text] [Related]
32. Promise of sodium-glucose co-transporter-2 inhibitors in heart failure with mildly reduced ejection fraction.
Shen X; Shen X
ESC Heart Fail; 2022 Aug; 9(4):2239-2248. PubMed ID: 35642772
[TBL] [Abstract][Full Text] [Related]
33. Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review.
Mentz RJ; Brunton SA; Rangaswami J
Cardiovasc Diabetol; 2023 Nov; 22(1):316. PubMed ID: 37974185
[TBL] [Abstract][Full Text] [Related]
34. Breakthroughs in the treatment of heart failure with mildly reduced and preserved ejection fraction.
Talha KM; Butler J
Clin Cardiol; 2022 Jun; 45 Suppl 1(Suppl 1):S31-S39. PubMed ID: 35789018
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors for heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials.
Cheema HA; Shafiee A; Athar MMT; Rafiei MA; Mehmannavaz A; Jafarabady K; Shahid A; Ahmad A; Ijaz SH; Dani SS; Minhas AMK; Nashwan AJ; Fudim M; Fonarow GC
Front Cardiovasc Med; 2023; 10():1273781. PubMed ID: 37900570
[TBL] [Abstract][Full Text] [Related]
36. The Efficacy and Safety of Sacubitril/Valsartan Compared to Valsartan in Patients with Heart Failure and Mildly Reduced and Preserved Ejection Fractions: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Kommu S; Berg RL
J Clin Med; 2024 Mar; 13(6):. PubMed ID: 38541798
[No Abstract] [Full Text] [Related]
37. Five-year mortality of heart failure with preserved, mildly reduced, and reduced ejection fraction in a 4880 Chinese cohort.
Chen S; Huang Z; Liang Y; Zhao X; Aobuliksimu X; Wang B; He Y; Kang Y; Huang H; Li Q; Yao Y; Lu X; Qian X; Xie X; Liu J; Liu Y
ESC Heart Fail; 2022 Aug; 9(4):2336-2347. PubMed ID: 35437939
[TBL] [Abstract][Full Text] [Related]
38. Characteristics and long-term prognosis of patients with reduced, mid-range, and preserved ejection fraction: A systemic review and meta-analysis.
Liang M; Bian B; Yang Q
Clin Cardiol; 2022 Jan; 45(1):5-17. PubMed ID: 35043472
[TBL] [Abstract][Full Text] [Related]
39. Clinical characteristics of hospitalized heart failure patients with preserved, mid-range, and reduced ejection fractions in Japan.
Shiga T; Suzuki A; Haruta S; Mori F; Ota Y; Yagi M; Oka T; Tanaka H; Murasaki S; Yamauchi T; Katoh J; Hattori H; Kikuchi N; Watanabe E; Yamada Y; Haruki S; Kogure T; Suzuki T; Uetsuka Y; Hagiwara N;
ESC Heart Fail; 2019 Jun; 6(3):475-486. PubMed ID: 30829002
[TBL] [Abstract][Full Text] [Related]
40. Beta-Blocker Use and Heart Failure Outcomes in Mildly Reduced and Preserved Ejection Fraction.
Arnold SV; Silverman DN; Gosch K; Nassif ME; Infeld M; Litwin S; Meyer M; Fendler TJ
JACC Heart Fail; 2023 Aug; 11(8 Pt 1):893-900. PubMed ID: 37140513
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
